Indomethacin antagonizes EP(2) prostanoid receptor activation in LS174T human colon cancer cells

European Journal of Pharmacology
Yuta IkawaToshihiko Murayama

Abstract

Increases in the level of cyclooxygenase (COX)-2 and prostanoids such as prostaglandin E(2) (PGE(2)) are considered biomarkers of colorectal cancer. Therefore, non-steroidal anti-inflammatory drugs (NSAID) have been used to reduce the risk of cancer development by reducing prostanoid biosynthesis as COX inhibitors. Along with their activity as COX inhibitors, NSAID have been reported to have other effects. One major NSAID, indomethacin, has been shown to have several effects independent of COX inhibition. To further examine the COX-inhibition-independent effects of indomethacin on colorectal cancer, we used human colon cancer LS174T cells, known to have express little COX-2 and have no detectable PGE(2) production. Here we show that indomethacin has a potential antagonizing effect on human EP(2) receptors. We believe this study raises the reasons to use indomethacin as a lead-compound for setting up another EP(2) receptor-specific antagonist as a relatively cost-efficient strategy for anti-cancer medication in the future.

References

Aug 10, 2000·The Journal of Biological Chemistry·J ShaoR N DuBois
Jan 5, 2001·British Journal of Pharmacology·D H WrightK M Metters
Oct 20, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·I TegederG Geisslinger
Jul 23, 2003·Trends in Pharmacological Sciences·Hiromichi Fujino, John W Regan
Aug 5, 2003·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Kinya Nagata, Hiroyuki Hirai
Nov 11, 2003·Life Sciences·John W Regan
Jan 31, 2004·Biochemical and Biophysical Research Communications·ShouWei Han, Jesse Roman
Jan 11, 2005·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jose U Scher, Michael H Pillinger
Apr 5, 2005·The Journal of Pharmacology and Experimental Therapeutics·Basil Rigas, Khosrow Kashfi
Jun 9, 2007·Biochemical and Biophysical Research Communications·Hiromichi FujinoToshihiko Murayama
Nov 7, 2008·Journal of Pharmacological Sciences·Takashi OridoToshihiko Murayama
Jul 25, 2009·British Journal of Pharmacology·R L JonesD F Woodward
May 21, 2011·British Journal of Pharmacology·Mark A Birrell, Anthony T Nials

❮ Previous
Next ❯

Citations

Feb 8, 2013·Cell & Bioscience·Viola AllajDaotai Nie
Jan 9, 2017·Colloids and Surfaces. B, Biointerfaces·Abbas AkhgariAli Nokhodchi
Mar 28, 2017·International Journal of Pharmaceutics·Dong JiaGareth R Williams
Jul 14, 2017·Journal of Drug Targeting·Chao Chen, Binbin Wang
Jan 27, 2019·International Journal of Molecular Sciences·Miyu IshiiNoriaki Nagai
Aug 11, 2018·Cancer Metastasis Reviews·Dali TongJun Jiang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.